Quick Answer
ArriVent BioPharma, Inc. reported Net Income Loss of -$166.31 million for the year ending 2025.
- ArriVent BioPharma, Inc. showed a decrease of -106.6% in Net Income Loss from 2024 to 2025.
- This data is from ArriVent BioPharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$12.17 million | Q2 2023: -$21.57 million | Q3 2023: -$14.40 million | Q1 2024: -$17.42 million | Q2 2024: -$21.87 million | Q3 2024: -$20.56 million | Q1 2025: -$64.39 million | Q2 2025: -$31.40 million | Q3 2025: -$34.98 million.
- Over the full 3 years of available data (2023 to 2025), ArriVent BioPharma, Inc.'s Net Income Loss has declined by 139.9%.
- Historical annual values: Fiscal year 2025: -$166.31 million | Fiscal year 2024: -$80.49 million | Fiscal year 2023: -$69.33 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: